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Interferon regulatory factor (IRF)-4 is a member of the IRF transcription factor 
family, whose expression is primarily restricted to lymphoid and myeloid cells.  In T-cells, 
IRF-4 expression is induced by T-cell receptor (TCR) cross-linking or treatment with 
phorbol-12-myristate-13-acetate (PMA)/Ionomycin, and IRF-4 is thought to be a critical 
factor for various functions of T-cells.  To elucidate the IRF-4 functions in human adult 
T-cell leukemia virus type 1 (HTLV-1)-infected T-cells, which constitutively express IRF-4, 
we isolated IRF-4-binding proteins from T-cells, using a tandem affinity purification 
(TAP)-mass spectrometry strategy.  Fourteen proteins were identified in the IRF-4-binding 
complex, including endogenous IRF-4 and the nuclear factor-kappaB (NF-B) family 
member, c-Rel.  The specific association of IRF-4 with c-Rel was confirmed by 
immunoprecipitation experiments, and IRF-4 was shown to enhance the c-Rel-dependent 
binding and activation of the interleukin-4 (IL-4) promoter region.   We also demonstrated 
that IL-2 production was also enhanced by exogenously-expressed IRF-4 and c-Rel in the 
presence of P/I, in T-cells, and that the optimal IL-2 and IL-4 productions in vivo was 
IRF-4-dependent using IRF-4-/- mice.  These data provide molecular evidence to support 
the clinical observation that elevated expression of c-Rel and IRF-4 is associated with the 
prognosis in adult T-cell leukemia/lymphoma (ATLL) patients, and present possible targets 
for future gene therapy. 
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Research Highlights 
● Interferon regulatory factor-4 binds to an NF-kappaB family member, c-Rel, in T cells. 
● The N-terminal half of c-Rel bound to the C-terminal IRF association domain of IRF-4. 
● IRF-4 and c-Rel bound to the interleukin-4 (IL-4) promoter region. 
● Exogenously-expressed IRF-4 and c-Rel enhanced the IL-2 production in T-cells. 









IRF-4, interferon regulatory factor-4; IFN, interferon; ISRE, IFN-stimulated response 
element; TCR, T-cell receptor; PMA, phorbol-12-myristate-13-acetate; I, Ionomycin; TAP, 
tandem affinity purification; IL-4, interleukin-4; HTLV-1, human adult T-cell leukemia virus 
type 1; ATLL, adult T-cell leukemia/lymphoma; NF-B, nuclear factor-kappaB; NFATc2 
(NFAT1), nuclear factor of activated T-cells; AZT, azidothymidine (zidovudine). 
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1. Introduction 
 Interferons (IFNs) are multi-functional cytokines that regulate the genes involved in 
viral infection defense, immune system activation, hematopoietic development and 
modulation of cell growth.  IFNs derive their effects through the transcriptional activation 
of target genes, which are regulated through IFN regulatory factors (IRFs).  In mammals, 
the members of the IRF family of transcription factors (IRF-1~IRF-9) bind to the 
IFN-stimulated response elements (ISREs) found in the promoter regions of IFN-stimulated 
genes (1). 
 The expression of IRF-4 is restricted to the immune system, and is induced by 
diverse mitogenic stimuli, including T-cell receptor (TCR) cross-linking or treatment with 
phorbol-12-myristate-13-acetate (PMA)/Ionomycin (I) (2-4). Mice deficient in the IRF-4 
gene (IRF-4-/-) exhibited profound defects in the functions of both B- and T-cells (5).  IRF-4 
plays crucial roles in multiple steps of B-cell differentiation. For instance, IRF-4 activates 
the immunoglobulin light-chain genes by binding a specific DNA sequence in the 3’ 
enhancer regions, in cooperation with the ETS-family transcription factor PU.1, and by 
repressing the key germinal center regulator, BCL6 (6,7).  Recently, IRF-4 was reported to 
be the master regulator gene in multiple myeloma, a malignancy of plasma cells (7,8).  
IRF-4 is also essential for several stages of T-cell and myeloid cell differentiation.  We, as 
well as other groups, have found that, in the absence of IRF-4, not only the development of 
Th2 but also that of a cDC subset, CD8-CD11b+, is severely impaired (9-12).  The IRF-4 
functions are regulated by several IRF-4-binding proteins.  FK506-binding protein 52 
(FKBP52) reportedly bound to IRF-4 in HTLV-1 (human T-cell leukemia virus type 
1)-infected T-cells, and repressed the IRF-4 function by preventing the nuclear translocation 
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and the target DNA binding of IRF-4 (13).  The IRF-4-dependent IL-4 induction in the 
presence of PMA and Ionomycin was enhanced by NFATc2 (NFAT1), and provided an 
important molecular function in T-helper cell (Th) differentiation (9).  NFATc1 (NFAT2) 
also activated the human IL-2 and IL-4 promoters in cooperation with IRF-4 (14).  Recently, 
it was reported that the elevated expressions of a nuclear factor-kappaB (NF-B) family 
member, c-Rel, and IRF-4 are associated with the prognosis in adult T-cell 
leukemia/lymphoma (ATLL) patients (15).  To elucidate the mechanism, we isolated 
IRF-4-binding proteins from the HTLV-1-infected T-cells (HUT102), using the tandem 
affinity purification (TAP) method (16).  We identified c-Rel, as a novel IRF-4-associated 
protein in T-cells.  We further examined whether IRF-4 activates the promoters of IL-2 (a 
T-cell growth factor) and IL-4 (an inducer of Th2 differentiation and growth) in cooperation 
with c-Rel in the stimulated T-cells. 
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2. Materials and Methods 
2.1. Cell culture and transfection 
 HUT102, an HTLV-1-infected human T-cell line, and EL-4, a murine thymoma cell 
line, were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), and transfected with the indicated plasmids by electroporation using a 
pipette-type electroporator, Microporator MP-100 (Digital Bio).  HEK293T cells were 
grown in 10% FBS-supplemented DMEM, and transfected with the indicated plasmids using 
the FuGENE 6 transfection reagent (Roche). 
2.2. Plasmid constructs 
 The full-length human IRF-4 cDNA (1-1356) (2), and the PCR-amplified DNA 
fragments, (1-405) and (404-1356), were inserted downstream of the FLAG tag in the 
pcDNA3 vector (Invitrogen).    The unique restriction enzyme, ApaI, was used to excise 
the N-terminal (1-1174) and C-terminal (1174-1860) regions from the full-length human 
c-Rel cDNA (1-1860)(17).  The fragments were inserted downstream of the HA tag in the 
pcDNA3 vector.  The IL-4-Luc reporter plasmid was constructed by inserting the 
PCR-amplified promoter region (-250 ~ +15) of the human IL-4 gene into the pGL2-Basic 
vector (Promega).  All constructs were confirmed by DNA sequencing. 
2.3. Preparation of cell extracts 
 Cell lysates were prepared by vigorous vortexing in 400 l of lysis buffer (20 mM 
Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP40), containing a protease inhibitor mix 
(Boehringer), 48 hour after transfection in a 6-well plate.   
For the preparation of the nuclear extract, HUT102 cells (1×10
6
 cells) were 
transfected with the indicated plasmids, and the nuclear proteins were extracted as described 
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previously (18). 
2.4. Immunoprecipitation and immunoblot analyses 
 The cell lysates were incubated with anti-FLAG M1 antibody-conjugated agarose 
beads (Sigma) for 2h at 4°C.  The nuclear extracts from HUT102 cells were incubated with 
5g of goat polyclonal anti-IRF-4 antibody (Santa Cruz Biotechnology), rabbit polyclonal 
anti-c-Rel antibody (Santa Cruz Biotechnology) or the corresponding control IgG antibody 
(Sigma), and Protein A Sepharose4B Fast Flow beads, for 3h at 4°C.  The 
immunocomplexes were extensively washed, and the co-precipitated proteins were eluted 
from the Sepharose beads by boiling in SDS sample buffer.  Each sample was resolved by 
SDS-PAGE, transferred to a PVDF membrane, and incubated with the indicated antibodies.  
Specific proteins were visualized with the appropriate HRP-conjugated antibodies and the 
ECL Plus detection system (Amersham Pharmacia Biotech). 
2.5. Chromatin immunoprecipitation (ChIP) 
The nuclear extracts from HUT102 cells were subjected to DNA-protein 
cross-linking with 1% formaldehyde for 5min.  After extensive washing, the samples were 
suspended in 500 μl of 150 mM NaCl, 25 mM Tris, pH 7.5, 5 mM EDTA, 1% Triton X-100, 
0.1% SDS, and 0.5% deoxycholate, and were sonicated.  After centrifugation at 14,000 rpm 
for 10 min at 4°C, the supernatants were precipitated with 25 μg anti-IRF-4 antibody, 
anti-c-Rel antibody, or the corresponding IgG (Sigma) (as a control), and Protein A 
Sepharose4B Fast Flow beads.  The amounts of precipitated DNA were quantified by PCR, 




2.6. Mice and primary T-cell activation 
 IRF-4 deficient (IRF-4–/–) mice were initially mated to C57BL/6 mice, and were 
maintained by intercrossing in the Laboratory Animal Center for Animal Research at 
Nagasaki University.  Mice were used at 5–6 weeks of age.  The animal experiments 
reported herein were conducted according to the Guidelines of the Laboratory Animal Center 
for Biomedical Research at Nagasaki University. 
 Freshly isolated CD4+ T-cells, from the spleens of C57BL/6 and IRF-4–/– littermates, 
were treated continuously with TNF- (5 ng/ml) for 6h.  The cells were then collected by 
centrifugation and cultured at a density of 1×106 cells/ml in six-well plates precoated with 
anti-TCR mAb (H57-597, 10 g/ml).  Cells were harvested at 4h for RNA analyses. 
2.7. RNA isolation and reverse-transcription PCR 
 Total RNA was extracted from the CD4+ T-cells and the HUT102 cells transfected 
with the indicated plasmids, using Isogen (Nippon Gene, Japan).  cDNA was generated 
from 1 g RNA, using reverse transcriptase.  The PCR primers used for human IL-2 were 
5'-TGTACAGCATGCAGCTCGC-3' and 5'-TGCTTCCGCTGTAGAGCTTG-3', those for 
mouse IL-2 were 5'-GAGTCAAATCCAGAAGATGCCGCAG -3' and 
5'-TGATGGACCTACAGGAGCTCCTGAG-3', those for mouse IL-4 were 
5'-CGAAGAACACCACAGAGAGTGAGCT-3' and 
5'-GACTCATTCATGGTGCAGCTTATCG-3', those for G3PDH were 
5'-CATCTGAGGGCCCACTGAAG-3' and 5'-TGCTGTTGAAGTCGCAGGAG-3', those 
for human -actin were 5'-AAGAGAGGCATCCTCACCCT-3' and 




Intraperitoneal injections and cell isolation 
 Complete and incomplete Freund's adjuvants (CFA/IFA) were purchased from Difco 
Laboratories.  An emulsion (100 l) of CFA in PBS was injected into each of the C57BL/6 
and IRF-4–/– littermates, followed by an injection of 100 l of IFA on the next day.  PBS 
alone was used as a negative control for all experiments.  The animals were sacrificed on 
day 6.  Lymphocytes were collected from the spleens.  Total CD4+ T-cells were purified 
using magnetic particles conjugated with anti-CD4 Ab (Imag Cell Separation System, BD 
Biosciences), as specified by the manufacturer.  This protocol provided cells with >99% 
purity, as assessed by flow cytometry.  Freshly isolated CD4+ T-cells were collected by 
centrifugation and cultured at a density of 1×106 cells/ml in six-well plates precoated with 
various concentrations of anti-TCR mAb (H57-597).  Cells were harvested at 16 h for 
cytokine assays, using sandwich ELISA.  For the mRNA preparation, the isolated CD4+ 
T-cells (2×105 cells/well) were stimulated in the 96-well paltes precoated with the indicated 




3.1. Identification of the proteins associated with IRF-4 by the TAP method, followed by 
mass spectrometry 
 To identify the proteins that associate with IRF-4 in T-cells, we purified the 
IRF-4–binding complex by the TAP method, as described previously (16), and in 
Supplemental Figs. 1S-3S.  We excised 30 well-separated bands that were specifically 
bound to IRF-4 from the gel, digested them with trypsin, and identified them by tandem 
mass spectrometry.  However, only fourteen bands, in addition to IRF-4, were identified 
with significant scores (p < 0.05) in the Swiss-Prot database, using the MASCOT search 
engine (Supplemental Table S1).  One of the peptide sequences acquired from the 
approximately 75–80 kDa protein band was matched to the human c-Rel proto-oncogene 
protein. 
3.2. Specific binding between IRF-4 and c-Rel 
 We further analyzed the binding of c-Rel to IRF-4, because the enhanced expression 
of both c-Rel and IRF-4 is associated with the prognosis in ATLL patients (15,16).  An 
HTLV-1 (human T-cell leukemia virus type 1)-infected T-cell line, HUT102, also expresses 
large amounts of IRF-4 and c-Rel.  As shown in Fig. 1A, the IRF-4 antibody 
co-precipitated c-Rel with IRF-4 more effectively in the presence of 250ng/ml PMA and 1 
M Ionomycin (P/I), as compared to the control IgG.  Conversely, the anti c-Rel antibody 
also co-precipitated IRF-4 with c-Rel independently of the P/I treatment, as compared to the 
control IgG (Fig. 1B).  Since the amounts of IRF-4 and c-Rel were not affected by the P/I 
treatment, the enhanced binding by P/I indicated that the P/I treatment induced a functional 
change in IRF-4, c-Rel, or other binding molecules.  In addition, we examined whether 
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IRF-4 directly binds to c-Rel, by over-expressing them in HEK293T cells.  The HA-tagged 
IRF-4 was specifically co-precipitated with the FLAG-tagged c-Rel, and the binding was 
enhanced in the presence of P/I (Fig. 1C). 
 Next, we examined the region of c-Rel that is responsible for its interaction with 
IRF-4, using HA-tagged deletion mutants of c-Rel (Fig. 2A,B).  The expected 68-kDa, 
39-kDa, and 34-kDa bands for the full-length, N-terminal half (1-1174), and C-terminal half 
(1174-1860) c-Rel constructs, respectively, were detected with an anti-HA antibody (Fig. 2B, 
left).  Each mutant c-Rel was co-expressed with FLAG-tagged IRF-4 in HEK293T cells 
and subjected to an immunoprecipitation assay.  As shown in the right panel of Fig. 2B, the 
full-length and the N-terminal half (1-1174) c-Rel constructs interacted with IRF-4, in 
contrast to the C-terminal half (1174-1860).  A strong band was detected always in the 
lanes containing FLAG-IRF-4.  This may be related to IRF-4, however, the binding of the 
N-termial half c-Rel to IRF-4 was specific, because the C-terminal half c-Rel was not 
co-precipitated with FLAG-IRF-4 using the anti-FLAG antibody.  On the other hand, the 
FLAG-tagged full-length and the C-terminal IRF association domain (403-1356) of the 
IRF-4 constructs co-precipitated HA-tagged c-Rel, in contrast to the N-terminal 
DNA-binding domain (1-405) of IRF-4 (Fig. 2C,D).  These results indicated the interaction 
between the N-terminal half of c-Rel, containing the Rel homology domain, and the 
C-terminal IRF association domain of IRF-4. 
3.3. IRF-4 and c-Rel cooperatively activate the IL-4 promoter 
 To explore the effects of c-Rel on the IRF-4 functions in vivo, we first examined the 
effects of c-Rel on the IRF-4-dependent IL-4 stimulation in HUT102 cells, using a luciferase 
reporter assay with an IL-4 promoter, because IRF-4 reportedly stimulated IL-4 expression 
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via a physical interaction with NFATc2 and/or NFATc1 (9,14).  As shown in Fig. 3A, the 
P/I treatment enhanced the basal IL-4 promoter activities (the open vs. filled bars), and the 
IRF-4 (lane 4), c-Rel (lane 6), and IRF-4+c-Rel (lane 8) activities were significantly 
enhanced by 1.88±0.18-, 2.11±0.07-, and 4.47±0.55-fold, respectively, as compared to the 
basal IL-4 promoter (lane 2).  Next, we tested the binding of IRF-4 and c-Rel to the IL-4 
promoter region, using a ChIP assay.  The amounts of the IRF-4 promoter region (-300 ~ 
-80) that co-precipitated with the anti-IRF-4, c-Rel, and control antibodies were determined 
semi-quantitatively, by changing the PCR cycle numbers (25, 30, and 35 cycles) in the 
presence or absence of P/I treatment (Fig. 3B).  The specific binding of IRF-4 and c-Rel to 
the IL-4 promoter region was observed, and the binding was enhanced by the P/I treatment, 
as compared to the control lanes.  The direct binding of IRF-4 and c-Rel each other, their 
binding to the IL-4 promoter, and the result that the increment of promoter activity by the 
both IRF-4 and c-Rel transfection (3.47-fold) was larger than the addition of each 
transfection (0.88- + 1.11- =1.99-fold), suggested that IRF-4 and c-Rel cooperatively 
activated the IL-4 promoter.  However, we could not deny the possibility of that IRF-4 and 
c-Rel worked independently on the IL-4 promoter activation.  The P/I treatment is often 
used to activate T cells, as well as the treatments with non-specific mitogens, specific T cell 
receptor (TCR) antigens, and the TCR antibodies.  The optimal concentration and duration 
of the reagents were determined by measuring the amounts of mRNA with real-time PCR 
using specific primer sets for IL-2, and IL-4, as shown in Supplemental Fig.S4.  When the 
EL-4 mouse T cells were treated with these reagents, Ionomycin only or PMA only was not 
enough to fully activate IL2 and IL4 promoters (Supplemental Figs. 4SA and 4SD).  PMA 
activated the IL-2 and IL-4 promoters dose-dependently in the presence of 1M Ionomycin, 
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and the mRNA expressions reached peak at 8h (Supplemental Figs. 4SB and 4SE).   The 
plate-bound 0.5g/ml anti-CD3, and 4g/ml anti-CD28 also activated the IL-2 and IL-4 
promoters (Supplemental Figs. 4SC and 4SF).  We used 250ng/ml PMA, and 1M 
Ionomycin, and plate-bound 0.5g/ml anti-CD3, and 4g/ml anti-CD28 for 4~8 hours to 
activate T cells otherwise indicated.  The treatments with the same amounts of P/I were also 
employed to stimulate effectively CD4+ T cells, and HUT102 cells. 
3.4. IRF-4 and c-Rel activate the IL-2 promoter to produce IL-2 
 IRF-4 is reported to stimulate IL-2 production as well as IL-4 (14).  To examine the 
effects of IRF-4 and c-Rel on the IL2-promoter, we introduced the plasmids encoding IRF-4 
and c-Rel into HUT102 cells.  We estimated the amount of IL-2 cDNA by applying 
different numbers of PCR cycles, after converting the mRNA to cDNA by reverse 
transcriptase, and evaluating the amount of -actin cDNA as the total amount of mRNA.  
As shown in Fig. 4A, substantial amounts of IL-2 cDNA were detected in the presence of P/I, 
as compared to those in the absence of P/I, and the amount of IL-2 cDNA was increased by 
exogenously expressing c-Rel or IRF-4.  To assess the data quantitatively, we employed the 
real-time PCR using IL-2 specific primers, and measured the mRNA expression of IL-2 
relative to -Actin (Fig.4B).  In the presence of P/I, the exogenous IRF-4 and c-Rel 
appeared to increase the expression of IL-2 mRNA, but the enhancing effects were not 
significant (p=0.116 and 0.134).  We think that the cooperation of IRF-4 with c-Rel was not 
observed, because HUT102 cells express a large amount of IRF-4, and thus the increases of 
IL-2 cDNA by IRF-4 or c-Rel were relatively small.  Indeed, in EL-4 cells, a cooperative 
effect of IRF-4 with c-Rel on IL-2 production was observed, by measuring the amounts of 
IL-2 produced from the cells transfected with the plasmids encoding IRF-4 and c-Rel, using 
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an ELISA (Fig. 4C).  However, any detectable amounts of IL-4 were not produced by any 
combinations of the reagents (Fig.4D).  The roles of IRF-4 and c-Rel in IL-2 and IL-4 
promoter activations are different in cell types and specific conditions.  For example, c-Rel 
is indispensable for the optimal IL-2 production in naïve T-cells, but is not required in for the 
IL-2 production in blast T-cells (19).  IRF-4 is also reported to differentially regulates the 
production of Th2 cytokines including IL-4 in naïve vs. effector/memory CD4+ T cells (20).  
The specific roles of the c-Rel and IRF-4 interaction in the activation of the IL-2 and IL-4 
promoters should be elucidated in specific cells and proper conditions. 
3.5. Optimal IL-2 amd IL-4 productions require IRF-4 in vivo 
Next, we examined the effects of IRF-4 on IL-2 and IL-4 productions in vivo using 
IRF-4–/– mice, because the IRF-4 and c-Rel interaction reminded us of the similar T-cell 
phenotypes between IRF-4–/– mice and c-Rel–/– mice (both mice exhibited defects in T-cell 
proliferation and IL-2 production in response to anti-CD3 stimulation).  In addition, 
Banerjee et al. reported that cytokine-mediated priming of naïve T-cells was c-Rel-dependent 
(19).  Therefore, we measured the IL-2 and IL-4 expressions in splenic CD4+ T-cells from 
normal and IRF-4–/– mice, by anti-CD3 stimulation with and without TNF- pretreatment.  
The amount of IL-2 mRNA in IRF-4-deficient cells (IRF-4–/–) was significantly lower than 
that in normal cells, as evaluated by quantitative real time PCR (WT) (Fig. 5A).  These 
results indicated that not only c-Rel but also IRF-4 is required for the optimal production of 
IL-2 in TNF--primed T-cells.  On the other hand, we could not detect any IL-4 mRNA by 
anti-CD3 stimulation even in TNF--primed T-cells from WT or IRF-4–/– mice (Fig. 5B). 
 We further examined the effects of complete Freund’s adjuvant (CFA)-mediated 
priming on the IL-2 production in splenic CD4+ T-cells.  Naive T-cells from CFA-primed 
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normal (WT), but not IRF-4–/–, mice produced high levels of IL-2 in response to anti-CD3 
stimulation (termed superinduction), dependent on the amount of TCR antibody (Fig. 5C).  
The priming effect of CFA was completely absent in the IRF-4-deficient T-cells.  To 
elucidate the mechanism of high IL-2 production, we examined the priming effects on the 
IL-2 promoter activity by measuring IL-2 mRNA with real time PCR (Fig.6A).  The IL-2 
mRNA amounts enhanced by TCR stimulation with the anti-CD3 and anti-CD28 antibodies 
were CFA-dependent in the WT mice-derived CD4+ T-cells.  The CFA-dependent 
superinduction was disappeared in IRF-4-/- mice, as reported in c-Rel-/- mice.  These 
indicated that IRF-4 as well as c-Rel is indispensable to fully activate IL-2 promoter in vivo. 
As for IL-4 regulation, the IL-4 production stimulated with TCR antibody was also 
dependent on the CFA priming in WT, although the amounts of IL-4 were much smaller than 
those of IL-2 (Figs. 5C and 5D).  The TCR activation-dependent IL-4 mRNA amounts were 
significantly lower in the IRF-4-/- mice compared to WT mice, but the CFA-dependence was 
not observed (Fig. 6B)  These suggested that the regulations of IRF-4 may be different in 
the IL-2 and IL-4 promoters.  The discrepancy between the protein and mRNA levels of 
IL-4 may be caused by the effects of IRF-4 on the stability of IL-4 protein, in addition to the 
effects on the promoter.  Another possibility of the discrepancy between the IL-4 protein 
and mRNA levels was due to the different sensitivities of the detection systems employed 
here.  The differences in mRNA expression measured at 4h after TCR stimulation may be 
not enough to assess the IL-4 promoter activities, considering that the IL-4 protein levels 
measured by ELISA reflect the continuous effects during 16 hours, and that the differences 
of IL-4 amounts were much smaller than those of IL-2. 
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4. Discussion 
 In the present study, we isolated a protein complex associated with IRF-4 in 
HTLV-1-infected T-cells using the TAP method, and showed that an NF-B family member, 
c-Rel, physically associates with IRF-4 and enhances the IRF-4-dependent IL-4 and IL-2 
promoter activation in some T-cells.  In addition, we mapped their binding sites to the 
C-terminal IRF association domain of IRF-4, and the N-terminal Rel-homology domain of 
c-Rel (Fig. 2).  Considering that these domains are used for interactions with other IRF 
members and NF-kB members, respectively, their interactions may affect the various 
functions of important transcription factors involved in cell growth, cell death, immunity, 
and other phenomena (1,21).  Although FKBP52, PU.1, E47, BCL6, STAT6, NFATc2, 
NFATc1, IBP, and MyD88 have been reported to bind to IRF-4 so far (9,13,21,22,23), the 
interaction of IRF-4 with c-Rel and their functional cooperation to enhance the IL-2 and IL-4 
promoter activities (Figs. 3 and 4) are noteworthy.  IRF-4 was indispensable for the optimal 
IL-2 and IL-4 productions in vivo was evident (Figs. 5 and 6), although the precise 
mechanism of the cooperation between IRF-4 and c-Rel in the regulation of the cytokine 
productions should be elucidated.  First, the elevated expression of IRF-4 and c-Rel is 
closely correlated with the exacerbation of ATLL (24) and antiviral therapy resistance in 
ATLL (15).  The antiviral therapy consists of azidothymidine (AZT) and IFN, which 
work at various points to prevent virus infection and proliferation.  Considering the fact that 
the IFN pathway can cross-talk with the IFN pathway (25), one possible mechanism 
related to the antiviral resistance is that IRF-4 antagonizes the INF-mediated 
IRF1-dependent suppression of the IL-4 promoter (26), by interacting with each other 
through the IRF association domains, or competing with each other for binding to the same 
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DNA sites (IFN-stimulated response elements (ISREs) are located at the proximal region of 
IL-4 promoter) (Fig. 3B) or a common adaptor, MyD88 (23).  On the other hand, c-Rel and 
IRF-4 themselves reportedly activate the IRF-4 promoter (8,27).  The enhancing loop and 
their cooperation may effectively activate the downstream genes, including the strong T-cell 
growth factor IL-2 (Fig. 4) and the proto-oncogene c-myc (8).  The determination of the 
interacting sites between IRF-4 and c-Rel will give precious information to develop specific 
reagents inhibiting T-cell growth in ATLL patients. 
Second, the IRF-4-dependent IL-4 induction in the presence of P/I was reportedly 
enhanced by the calcineurin-regulated transcription factors NFATc2 (NFAT1) and/or 
NFATc1 (NFAT2), and may partly explain the crucial roles of IRF-4 in Th2 differentiation 
(9,12,25).  However, we could not detect any specific binding of endogenous IRF-4 or 
c-Rel with NFATc1 or NFATc2 in the presence or absence of P/I treatment in HUT102 or 
EL-4 T-cells, although the exogenously-expressed NFATc1 and NFATc2 showed very weak 
binding to IRF-4 even in the presence of P/I in 293T cells (data not shown).  Considering 
the redundant and complicated effects of NFAT protein families (NFATc1, NFATc2, and 
NFAT4 are expressed in T-cells) (28) on the IL-4 promoter activity, and that the substantial 
interaction of IRF-4 with c-Rel to activate the IL-4 promoter did not require P/I treatment 
(Figs. 1~3), we think the P/I-dependent enhancement is not simply because of the binding of 
IRF-4 with the NFATs.  IRF-4 was indispensable for the optimal IL-4 production, but the 
mechanism was not explained only by the effects on the IL-4 promoter activation (Figs. 
4~6). 
In contrast, our data suggested that IRF-4 worked mainly on the IL-2 promoter 
activation, and the activation was may be in cooperation with c-Rel.   The IL-2 promoter 
18 
activation by IRF-4 required P/I treatment or TCR stimulation with cytokine priming (Fig. 
4~6).  These results suggested that qualitative changes of IRF-4 and/or c-Rel, their possible 
interacting molecules, and the chromatin structure in the IL-2 proximal promoter region by 
such as phosphorylation, acetylation, and demethylation may be necessary for optimal IL-2 
promoter activation (29).  The absence of ISRE site in the IL-2 proximal promoter region, 
compared to the IL-4 promoter, may be involved in the difference.  In addition, c-Rel was 
recently reported to be required for the development of thymic Foxp3+ CD4 regulatory 
T-cells (Treg) (30), and Foxp3-dependent IRF-4 induction in Treg is thought to be important 
for the Treg function to control the Th2 response (31).  Therefore, regulating the interaction 
between IRF-4 and c-Rel by manipulating the molecules may help to differentiate from 
pluripotent T-cells into specific lineage to treat various diseases (32). 
In conclusion, the elucidation of the physical and functional cooperation between 
IRF-4 and c-Rel to activate of the IL-4 and IL-2 genes in T-cells, is important for future gene 
therapy for ATLL by abolishing their growth effects, and to present promising targets for 
adoptive immunotherapy by regulating specific T-cell development. 
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Fig. 1  IRF-4 and c-Rel binding.  (A, B) Nuclear extracts from HUT102 cells (5x106), 
cultured for 8h in the presence or absence of 250ng/ml PMA and 1 M Ionomycin (P/I), 
were immunoprecipitated with the IRF-4 antibody (A) or the c-Rel antibody (B).  The 
SDS-PAGE fractionated proteins were blotted with the c-Rel antibody (A) and the IRF-4 
antibody (B), respectively.  (C) HEK293T cells (4x105) were transfected with an 
HA-tagged IRF-4 expression plasmid and/or Flag-tagged c-Rel expression plasmid (500ng 
each), using the FuGENE reagent.  Two days after transfection, the cells were incubated for 
8h in the presence or absence of P/I.  The nuclear extracts were prepared, 
immunoprecipitated with an anti-FLAG antibody, and blotted with an anti-HA antibody. 
 
Fig. 2  Determination of IRF-4 and c-Rel binding sites.  (A, B) HA-tagged full-length, 
N-terminal half (1-1174), and C-terminal half (1174-1860) c-Rel constructs (500ng each) 
were introduced with FLAG-tagged full-length IRF-4 (500ng) into 4x105 HEK293T cells in 
6-well plates.  The lysates (B, left panel), and the c-Rel deletion mutants 
co-immunoprecipitated with IRF-4 by the anti-FLAG antibody (B, right panel) were detected 
with an anti-HA antibody.  The arrows indicate the HA-c-Rel bands, and the arrowhead 
shows a non-specific band.  (C, D) FLAG-tagged full-length, N-terminal region (1-405), 
and C-terminal region (403-1356) IRF-4 constructs (500ng each) were introduced with 
HA-tagged full-length c-Rel (500ng) into 4x105 HEK293T cells in 6-well plates.  The 
lysates (D, left panel), and the c-Rel co-immunoprecipitated with the IRF-4 deletion mutants 
by the anti-FLAG antibody (D, right panel), were probed with an anti-HA antibody.  The 
arrows and arrowhead indicate the FLAG-IRF-4 bands, and the HA-c-Rel band, respectively. 
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Fig. 3  IRF-4 and c-Rel co-operatively activate the human IL-4 promoter.  (A) 
HUT102 cells (2x105) were transfected with a luciferase reporter construct driven by the 
human IL-4 promoter (-250 ~ +15) (1g) with/without IRF-4, and c-Rel expression plasmids 
(200 ng each) by electroporation.  Two days after transfection, the cells were incubated for 
8hr in the presence or absence of 250ng/ml PMA and 1 M Ionomycin (P/I), and the 
luciferase activities were measured.  Results show the mean ± S.E. of three independent 
experiments.  (B) The chromatin immunoprecipitation (ChIP) assay was performed using 
HUT102 cells (5x106) treated with/without P/I for 8h, with anti-IRF-4 and anti-c-Rel 
antibodies.  The amount of specifically precipitated DNA was determined semi-quantitively, 
by changing the PCR cycle numbers (25, 30 and 35 cycles) with primers specific for the IL4 
promoter (-300～-80).   
 
Fig. 4  IRF-4 and c-Rel activate the IL-2 promoter to produce IL-2. 
HUT102 cells (4x105) were transfected with IRF-4 and c-Rel expression plasmids (2g 
each) by electroporation.  Two days after transfection, the cells were incubated for 8hr in 
the presence or absence of 250ng/ml PMA and 1 M Ionomycin (P/I), and the total RNA 
was extracted.  The amounts of IL-2 and -actin cDNAs were estimated by applying 
different numbers of PCR cycles (A), and measured by real time PCR using the specific 
primers (B).  The EL-4 cells (2x105) were transfected with IRF-4 and c-Rel expression 
plasmids (500 ng each) by electroporation.  Two days after transfection, the cells were 
incubated for 8hr in the presence or absence of P/I, and the amounts of IL-2 (C), and IL-4 
(D) in the supernatant were measured by sandwich ELISA.  The data shown are 
representative of three independent experiments done in triplicate.  
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Fig. 5  IRF-4 is indispensable to produce IL-2 and IL-4 production in vivo. 
(A, B) TNF--mediated priming of naive T-cells requires IRF-4.  CD4+ T-cells were 
purified from the spleens of C57BL/6 mice (WT) or IRF-4–/– mice, and were activated with 5 
ng/ml of TNF- or with TNF- plus anti-CD3 antibody (10 g/ml) for 6h.  The relative 
amounts of IL-2 (A) and IL-4 (B) mRNA normalized to the quantity of G3PDH mRNA were 
determined by real-time PCR, using the reverse-transcribed cDNAs.  The data shown are 
representative of three independent experiments done in triplicate.  (C, D) 
Adjuvant-mediated priming of naive T-cells also requires IRF-4.  C57BL/6 mice (WT) and 
IRF-4–/– mice were injected intraperitoneally with complete Freund's adjuvant (CFA) or 
saline (PBS), followed by a second injection of incomplete Freund's (IFA) or PBS, 
respectively.  Six days later, splenic T-cells were activated with various amounts of 
plate-bound anti-TCR antibody, and the levels of IL-2 (C), and IL-4 (D) were determined 
by an ELISA.  Data shown are representative of three independent experiments.   
 
Fig. 6  Effects of IRF-4 on the IL-2 and IL-4 promoters in vivo. 
C57BL/6 mice (WT) and IRF-4–/– mice were injected intraperitoneally with complete 
Freund's adjuvant (CFA) or saline (PBS), followed by a second injection of incomplete 
Freund's (IFA) or PBS, respectively.  Six days later, splenic T-cells were activated with 
various amounts of plate-bound anti-CD3, and anti-CD28 antibodies, and the relative 
amounts of IL-2 mRNA (C), and IL-4 mRNA (D) normalized to the quantity of -Actin 
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Materials and Methods 
Plasmid constructs and transfection 
 For the TAP purification, HUT102 cells were transfected with the TAP-IRF4 plasmid 
using the TransFast Transfection Reagent (Promega).  The TAP tag cassette consists of, N 
to C termini, Calmodulin-binding peptide (CBP), the tobacco etch virus, TEV protease 
recognition sequence (TEV site), and two copies of IgG binding domain of Staphylococcus 
aureus Protein A (IGB).  A full-length human IRF-4 cDNA lacking the TGA stop codon 
was inserted before the TAP tag cassette site of the pcDNA3.1-derived plasmid.   
Preparation of cell extracts 
 HUT102 cells (1×10
8
 cells) transfected with or without the TAP-tagged IRF-4, were 
collected, suspended in 2ml of buffer A (10mM HEPES, pH7.9, 10mM KCl, 0.1mM EDTA, 
1mM DTT, and 0.5mM PMSF), and then lysed in the presence of 0.6% Nonidet P-40 by 
vortex.  The nuclei were collected by brief centrifugation, and were resuspended in 800 l 
of buffer C (20mM HEPES, pH7.9, 400mM NaCl, 1mM EDTA, 1mM DTT and 1mM 
PMSF).  The nuclear proteins were extracted by incubating for 15min at 4°C, and cleared 
by centrifugation at 15,000 rpm for 5 min at 4°C. 
Tandem affinity purification (TAP) 
 The purification was performed by incubating 800l of the nuclear extract with 
100l of IgG Sepharose beads (Amersham Biosciences) in 5ml of IPP150 buffer (10mM 
Tris-HCl, pH8.0, 150mM NaCl, and 0.1%NP-40) for 2h at 4°C.  The mixture was poured 
into an Econocolumn (Bio-Rad), and the beads were washed extensively with IPP150 buffer 
2 
and once with TEV cleavage buffer (10mM Tris-HCl, pH8.0, 15mM NaCl, 0.1%NP-40, 
0.5mM EDTA, and 1mM DTT).  The beads were suspended in 1ml of TEV cleavage buffer 
and were incubated with 100 units of TEV protease (Invitrogen) by rotation for 2h at 16°C.  
The eluate was recovered by centrifugation, and then incubated with the 100l of calmodulin 
beads in 3ml of calmodulin binding buffer (10mM Tris-HCl, pH8.0, 150mM NaCl, 
0.1%NP-40, 10mM 2-mercaptoethanol, 1mM magnesium acetate, 1mM imidazole, and 
2mM CaCl2) by rotating for 1h at 4°C.  After poured into second Econocolumn, the beads 
were washed extensively with calmodulin binding buffer, the IRF-4-binding proteins were 
eluted with 1ml of calmodulin elution buffer containing 2mM EDTA instead of 2mM CaCl2. 
Tryptic digestion, peptide extraction, and mass spectrometric analysis 
 After negative-staining, the bands were excised, dehydrated in acetonitrile (WAKO, 
Japan) and deoxidized in DTT and ammonium carbonate buffer.  Sequencing Grade 
Modified Trypsin (Promega) was added to each tube, and the reactions were incubated 
overnight at 37°C.  The digested peptides were extracted from the gel with 50% acetonitrile 
containing 5% trifluoroacetic acid (TFA) and were dried.  Tryptic peptides were sequenced 
by tandem mass spectrometry on a QSTAR® XL Hybrid LC/MS/MS System, hybrid 
quadrupole time of flight (Q-TOF) mass spectrometer (Applied Biosystems) and automated 
data analysis system.  All of the MS/MS spectra identified from the peptide fragmentation 
data by the Analyst® QS software were searched against the protein sequence database 
maintained at the National Center for Biotechnology Information, using the MASCOT 
program (http://www.matrixscience.com), to identify the proteins. 
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Results 
Identification of the proteins associated with IRF-4 by the TAP method, and subsequent 
mass spectrometry 
 To identify the proteins that associate with IRF-4 in T-cells, we purified 
IRF-4–binding complex by the TAP method, as described previously.  Supplemental Fig.1S 
illustrates the purification procedures of specific binding proteins to the target TAP-tagged 
protein (TAP-tagged IRF-4) using two different affinity columns.  The final eluates 
containing the IRF-4-binding protein complex (Supplemental Fig.2S-B, EGTA) were 
separated on a 4–20% SDS-PAGE gradient gel and visualized with a Negative Gel Stain MS 
Kit (Supplemental Fig.2S, IRF4-TAP).  Compared to the control experiment (WT) using the 
same amount of HUT102 cells without transfection of the target TAP-tagged IRF4 
expression plasmid, as many as 50 bands were stronger than the control.  We excised well- 
separated 30 bands from the gel, digested by trypsin and identified by tandem mass 
spectrometry.  However, only the fourteen bands in addition to IRF4 were identified with 
significant scores (p < 0.05) in the Swiss-Prot database, using the MASCOT search engine 
(Supplemental Table S1).  One of the peptide sequences acquired from the approximately 
75–80 kDa protein band was matched to the human c-Rel proto-oncogene protein with 160 
Mowse score and covering 13% of the c-Rel entire 560 amino acids sequence in independent 
7 peptides (p=0.001). 
Optimization of T-cell activation with PMA, and Ionomycin, and T-cell receptor (TCR) 
antibodies.   
We optimized the T-cell activations using EL-4 mouse T-cells, and used 250ng/ml 
4 
PMA, and 1M Ionomycin, and plate-bound 0.5g/ml anti-CD3, and 4g/ml anti-CD28 for 
4~8 hours to activate T cells otherwise indicated.  The treatments with the same amounts of 
P/I, were also employed to stimulate effectively CD4
+
 T cells, and HUT102 cells. 
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Figure legends 
Supplemental Fig. S1  Purification scheme of IRF-4-binding proteins by the TAP 
strategy.  The nuclear extracts prepared from cells expressing the TAP-tagged IRF-4 are 
subjected to two successive purification steps.  The first column traps the IRF-4-TAP 
complex specifically, and the complex is eluted with TEV protease, leaving non-specific 
proteins that bind to IgG beads.  The IRF-4-TAP complex binds to the second 
calmodulin-coated beads, to remove the TEV protease and non-specific TEV-cleaved 
fragments.  Finally, the highly-purified IRF-4-binding complex was eluted by reducing 
calcium concentration with EDTA.  X, Y, Z: possible IRF-4 binding protein. ● : 
non-specific proteins, ■: non-specific proteins that bind to IgG beads, ▼: non-specific 
TEV-cleaved fragments. 
 
Supplemental Fig. S2  Actual purification of IRF-4-binding proteins by the TAP 
strategy. 
(A) TAP-tagged human IRF-4 was expressed in HUT-102, an HTLV-1-infected human T cell 
line constitutively expressing IRF-4.  The nuclear (N) and cytoplasmic (C) extracts of 
HUT102 cells transfected with the TAP-tagged IRF-4 expression vector (IRF-4-TAP) and 
non-transfected HUT102 cells (WT), were separated by 9% SDS-PAGE, blotted with an 
anti-IRF-4 antibody. 
(B) Aliquot of each purification step was separated by 9% SDS-PAGE, and blotted with the 
anti-IRF-4 antibody to monitor the purification procedure.  Input, input; FT1 and FT2, flow 
through fractions from the 1st and 2nd affinity pcolumns, respectively; TEV, the IRF-4-TAP 
6 
complex released with TEV protease treatment; EDTA, the IRF-4-TAP complex eluted from 
the calmodulin-coated beads with EGTA. 
 
Supplemental Fig. S3  SDS-PAGE and negative-staining of the purified IRF-4-binding 
proteins.  The TAP-purified proteins from the extracts of cells transfected with the 
TAP-tagged IRF-4 expression plasmid (IRF-4-TAP) or non-transfected cells (WT), were 
fractionated on a 4–20% SDS-PAGE gradient gel and visualized with a negative-stain kit.  
About 30 protein bands were analyzed by tandem mass spectrometry (Hybrid LC/MS/MS 
System); the corresponding gene names identified by the MASCOT search engine 
(http://www.matrixscience.com), and a molecular weight marker are shown. 
 
Supplemental Fig. S4  Optimization of T-cell activation with PMA, and Ionomycin, 
and T-cell receptor (TCR) antibodies.  The EL-4 mouse T cells were treated with the 
indicated PMA, and Ionomycin, the treatment Ionomycin only or PMA for 8h, and the 
relative amounts of IL-2 (A) and IL-4 (D) mRNA normalized to the quantity of -Actin 
mRNA were determined by real-time PCR, using the reverse-transcribed cDNAs.  The IL-2 
(B) and IL-4 (E) mRNA amounts relative to -Actin mRNA were measured after the 
treatments of 250ng/ml PMA, and 1M Ionomycin for the indicated time.  The EL-4 T 
cells were stimulated with the plate-bound anti-CD3 (0.5 g/ml) and anti-CD28 antibodies 
(4 g/ml) for the indicated time, and the IL-2 (C) and IL-4 (F) mRNA amounts -Actin 
mRNA were measured.  The data shown are representative of three independent 
experiments done in triplicate. 
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Supplemental Table S1.  Summary of the IRF-4 associating proteins. 
 
NCBIGI# Protein identification Protein(MW)  Scorea %coverage 
 Signaling intermediates 
23503048 Cleavage and polyadenylation specificity factor (CPSA) 160782 44 4 
1491699 78kDa glucose-regulated protein precursor (GRP78) 72288 38 3 
34978357 Heat shock 70kDa protein 6 (HSP76) 70984 79 7 
123648 Heat shock 71kDa protein (HSP7C) 70854 329 27 
3183544 Polyadenylate-binding protein 1 (PABP1) 70626 122 9 
 Transcription regulators 
55977747 Heterogeneous nuclear ribonucleoprotein M (hnRNPM) 77333 72 5 
548720 c-Rel proto-oncogene protein (c-Rel) 68476 160 13 
114762 Nucleophosmin (NPM) 32555 122 13 
 Ribosomal subunit 
133041 60S acidic ribosomal protein P0 (L10E) 34252 116 19 
21759409 Exosome complex exonuclease RRP43 30020 77 7 
133021 60S ribosomal protein L7 (RL7) 29207 52 4 
 GDP/GIP binding protein 
544231 Elongation factor 1-alpha 2 (EF1A) 50438 46 2 
 SDR(short-chain dehydrogenase/reductase) enzyme 
3915733 Dehydrogenase/reductase SDR family member 2 (HEP27) 27290 218 22 
 Others 
57015374 Nuclear protein ZAP3 219849 133 3 
 
The candidate proteins with significant scores (p < 0.05) in the Swiss-Prot database, using the MASCOT 
search engine are summarized.  
aMASCOT computes the probability as a significance score, with higher scores meaning that the observed 
match between the experimental data and the mass values calculated from a candidate peptide or protein 
sequence is not a random event (http://www.matrixscience.com/). 
NCBI gene identification numbers (GI#), molecular weights (MW), percentage of peptide coverage (% 

























































































SDR family member 2
Nuclear protein ZAP3
Cleavage and polyadenylation specificity factor
c-Rel proto-oncogene protein
Heterogeneous nuclear ribonucleoprotein M
78 kDa glucose-regulated protein precursor
Heat shock cognate 71 kDa protein
Heat shock 70 kDa protein 6
Polyadenylate-binding protein 1
Interferon regulatory factor-4 (IRF-4)
Elongation factor 1-alpha 2
60S acidic ribosomal protein P0
Exosome complex exonuclease RRP43 
















































































































































0h 4h 8h 24h
m
R
N
A
 e
x
p
re
s
s
io
n
 (
IL
4
/b
-A
c
ti
n
)
Time
C F
E
D
